Polypharmacy
Conditions
Interventions
Group 1: The microbiome of patients over the age of 60 with polypharmacy (more than 5 non-antibiotic medications) with and in a control group without current antibiotic medication will be investigated
Sponsors
Universitätsklinik Tübingen
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: - capable of giving consent or consent by patient representative additionally for subject group 1.: - long-term use of 5 or more non-antibiotic medications (home medication) additionally for subject group 2: - long-term use of 5 or more non-antibiotic medications (home medication) and current intake of at least one antibiotic
Exclusion criteria
Exclusion criteria: - Acute cancer - Diagnosis of other diseases or conditions that are associated with changes in the intestinal microbiota, e.g. chronic inflammatory bowel disease, artificial bowel outlet (stoma), current diarrhea - Use of antibiotics in the last 3 months before recruitment additionally for subject group 3: - acute illness or inpatient treatment in hospital - Permanent intake of more than 2 medications (home medication) additionally for subject group 4: - Permanent intake of more than 2 medications (home medication)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This exploratory pilot study will investigate the influence of polypharmacy compared to a control group on the gut microbiome and its function in a geriatric population. | — |
Secondary
| Measure | Time frame |
|---|---|
| Data will be collected on the following variables: Metagenome data, influence of polypharmacy on the gut microbiome, its composition and function, analysis of drug-microbiome interactions by metabolome analysis, and functional in vitro assays. | — |
Countries
Germany
Contacts
Public ContactJennifer Herrmann
Universitätsklinikum Tübingen
Outcome results
None listed